RED HERRING: Not an offer to invest. Professional Investors, Qualified Institutional Buyers, Accredited Investors, by Invitation only.



Advanced clinical PET imaging for Cancer, Heart Disease
and Brain Disease.

Impact Strategy

Advanced biomedical discovery data resources for scientists and doctors.
Impact Strategy


Ten billion vaccines, in the next ten years, on open manufacturing platform.
Impact Strategy


ARIES. The Aligned Responsibility International Education Service™
Pro Bono


Life. Health. Prosperity.

Predictable market and manageable risks. Competitive expected financial performance. Extreme global social impact.


The number of tests needed globally over a year to supply a weekly testing regimen would be equivalent to less than half the number of cans of soda consumed annually. – WEF

Affordable and accessible for all.


For eCAM Centers in cooperation with leading global biotech and pharmaceutical industry tenants.

With pro bono ORION services.


For advanced medical imaging,
for patients and their doctors;
cancer, heart disease, brain disease.

With pro bono medical discovery access.


For leading brands for marketing of global sustainability to young people; Millennials and Gen Z consumers.

With pro bono ARIES services.


With advanced vaccine technologies
for efficient deployment of vaccines
for infectious disease and cancer.

Affordable and accessible for all.

For profitable impact investment, our unique strategy is easy to understand:

1. ECAM private equity. eCAM Center advanced molecular medical imaging services for doctors and their patients for, cancer, heart disease, brain disease patients

2. ECAM-R private equity. Diversified real estate investment with planned REIT rules tax efficient investor dividends of 90% of rental profits.

• eCAM Medical Plaza real estate operating platform and ecosystem for leading healthcare and pharmaceutical tenants, with eCAM Center anchor tenant.

• eCAM Global Impact Plaza real estate operating platform for leading global brand tenants. We enable access to, and engagement with, Millennial and Gen Z global customer base. We offer leading brands a unique platform to engage truly wonderful and sustainable brand reputation, with extraordinary innovation and meaningful purpose, for sharing inspiring sustainability experiences, for people, for customers, for stakeholders, for vast collective benefit to the global commons.

For Discussion Purposes. Not an offer to invest. See Red Herring Disclosure Herein. For QIBs and Accredited Investors only.

The Mission of eCAM Biomed Global Impact Fund (1:20)

Think Good Data.
Transparent. Real-time. Immutable. Recorded. Administrated. Audited. Regulated. Private. Secure. Trustworthy. Data.
Impact invest in eCAM Biomed Global Impact Fund with MY ECAM.
Invest in our common future. Private equity for people, planet, principle, prosperity.


For Professional Investors, Qualified Institutional Buyers, and Accredited Investors only. Subject to KYC/AML qualification procedures.

For Professional Investors, QIBs and Accredited Investor inquiry: please send us an invite on Linkedin to book a confidential introductory meeting online.

Red Herring Disclosure Brief: In the UK and Guernsey, ECAM is a direct broker dealer of our regulated securities for Qualified Institutional Buyers (QIBs) and Accredited Investors only. We offer eCAM Biomed Global Impact Fund financial products directly to you. (FCA approved person. Controlled function: CF30 Customer.) Our due diligence process with MY ECAM is simple, fast and true. Think good data. Think can do. We work directly with you, to support you and your investment committee analysis and potential commitment procedures. We have no sell-side placement agent costs. We rebate these efficiency savings directly to your bottom line, or you may consider to opt-in these savings as a pro bono contribution to social benefit of ORION or ARIES or any other charity. Learn more about competitive expected financial returns with extraordinary social impact from eCAM Biomed Global Impact Fund. for a confidential private invitation. Not an offer to invest. See Private Placement Memoranda. By invitation to Professional Investors, QIBs and Accredited Investors only. Please see detailed Red Herring Disclosure below.


In the United Kingdom, this communication is issued by eCAM Biomed Global Impact Limited and approved by Robert Quinn Advisory LLP, which is authorised and regulated by the UK Financial Conduct Authority (“FCA”). eCAM Biomed Global Impact Limited is an Appointed Representative of Robert Quinn Advisory LLP.
This material constitutes a financial promotion for the purposes of the Financial Services and Markets Act 2000 (the “Act”) and the handbook of rules and guidance issued from time to time by the FCA (the “FCA Rules”). This material is for information purposes only and does not constitute an offer to subscribe for or purchase of any financial instrument. The Firm neither provides investment advice to, nor receives and transmits orders from, persons to whom this material is communicated nor does it carry on any other activities with or for such persons that constitute “MiFID or equivalent third country business” for the purposes of the FCA Rules. All information provided is not warranted as to completeness or accuracy and is subject to change without notice. This communication and any investment or service to which this material may relate is exclusively intended for persons who are Professional Clients or Eligible Counterparties for the purposes of the FCA Rules, or fall into a relevant category under COBS 4.12 in the FCA Rules and other persons should not act or rely on it. This communication is not intended for use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.


Qualified Institutional Buyers and Accredited Investors by invitation only with KYC/AML compliance by Fund Admin.
Not an offer to invest. See ECAM-R and/or ECAM Private Placement Memoranda (PPM). Significant risk of investment.
The material on this website is intended for informational purposes only, does not constitute investment advice or analysis, or a recommendation, or an offer of solicitation, and is not the basis for any contract or other agreement to make any investment, or for eCAM Biomed Global Impact Fund to enter into or arrange any type of transaction. Forward-Looking Statements: The contents of this website may contain forward looking statements that are based on management’s beliefs, assumptions, current expectations, estimates, and projections, eCAM Biomed Global Impact Fund itself or its investments. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward looking statements.
eCAM Biomed Global Impact Limited
Reference number: 926731
Type: Appointed Representative
Current status: Appointed representative of Robert Quinn Advisory LLP (“the Principal”) which is authorised and regulated by the FCA.
This is a firm or individual that can act on behalf of another firm (its principal) that is authorised in the UK or regulated in another EEA country. The principal is responsible for the appointed representative’s activities.
Effective date: This is the date from which the Current Status has applied. 26/05/2020
* In its capacity of an Appointed Representative of the Principal firm, eCAM Biomed Global Impact Limited is only permitted (i) to carry on the regulated activities of “advising on investments” and “arranging deals in investments”; and (ii) to market investment services and funds to professional clients and eligible counterparties
FCA approved person.
The individual named below is approved under section 59 of the Financial Services and Markets Act (FSMA) 2000 to perform the Controlled Function (set out below and, if applied for, will be noted as responsible for Insurance Distribution):
Individual name: Peter Albert Jensen
Individual Reference Number: PXJ84051
Date of Birth : 17/06/1958
Firm Name                               FRN         Controlled Function(s)   Date(s)
Robert Quinn Advisory LLP   548030   CF1 Director (AR).            16/06/2020
Robert Quinn Advisory LLP   548030   CF30 Customer                 16/06/2020
COVID-19 Pandemic Report by ECAM. FOR EDUCATIONAL AND SOCIAL BENEFIT PURPOSES ONLY. Curated news, reports, and opinions, the COVID-19 Report by ECAM is published for educational and social benefit purposes only, not for profit. The global social Impact Mission of ECAM is explained here. The mission of the eCAM Biomed Global Impact Fund is to manage investor capital for competitive financial performance with scalable global social impact. Not an offer to invest. Qualified institutional buyers and accredited investors only. Millions of lives at Risk. Trillions of dollars lost. It is vital to prepare for pandemics.
DISCLOSURE | eCAM Biomed | MY ECAM | Real-time DLT State Machine for benefit of Investors, Stakeholders, Partners, Service Providers. One, real-time, online, distributed, encrypted, immutable, report of the truth. MY ECAM evidences the continuous private development and operational and financial state of ECAM private equity business, including real-time Private Placement Memoranda (PPM).
FOR DISCUSSION PURPOSES ONLY. IMPORTANT RED HERRING DISCLAIMER. This information should be regarded as being of a preliminary character only, and subject to updating. It has been prepared on the assumption that the legal and tax structures required to conduct the activities of eCAM Medical Plaza Global Impact Private Equity Fund (referred to in this handout as “eCAM REIT”, “ECAM-R” or “eCAM Medical Plaza”), and separately, the eCAM Sukuk Bond, have already been fully implemented and that all regulatory, tax and other clearances have been obtained. In particular, eCAM REIT will require to be registered as a closed-ended private investment fund (“PIF”) pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended (“POI Law”) and the Private Investment Fund Rules 2016 issued by the Guernsey Financial Services Commission, and its general partner will require to be licensed pursuant to the POI Law. The structure will have been implemented prior to the first closing of eCAM REIT. If there are inconsistencies between statements in this handout and the provisions of the relevant Private Placement Memorandum or Limited Partnership Agreement in relation to eCAM REIT or the other investment options described in this handout, the latter will prevail over this handout. Any other materials presented to prospective investors in relation to eCAM REIT or the eCAM Sukuk Bond on or prior to the date of this document are deemed to be subject to the same red herring disclaimer set out in this document. This handout is issued by the manager of eCAM REIT, eCAM Biomed Global Impact Investment Management Limited (the “Manager”) on a confidential basis to selected sophisticated and/or high net worth investors for the sole purpose of providing information about an investment in eCAM REIT and/or other investment options in relation to the eCAM Biomed Global Impact Fund structure. This handout should not be distributed, published or reproduced, in whole or in part, nor should its contents be disclosed by recipients to any other person. This document has been prepared to obtain an indication of interest only. It does not constitute an offer or invitation to subscribe or purchase limited partnership interests or other investments and the information contained herein is subject to updating, amendment and verification. It should not be relied upon by any persons for any purpose. An offer of limited partnership interests will only be made on the despatch by the general partner of a partnership agreement along with a form of adherence. Prospective investors must rely on their own examination of the legal, accounting, taxation, financial and other consequences of an investment in the eCAM REIT or other investment options, including the merits of investing and the risks involved. Prospective investors should not treat the contents of this handout as advice relating to legal, accounting, taxation or investment matters and are advised to consult their own professional advisors concerning the acquisition, holding or disposal of commitments in eCAM REIT or other investment options. All statements of opinion and/or belief contained in the handout and all views expressed and all projections, forecasts or statements relating to expectations regarding future events or the possible future performance of eCAM REIT or other investment options represent the Manager’s own assessment and interpretation of information available to it as at the date of this handout. No representation is made or assurance given that such statements, views, projections or forecasts are correct or that the objectives of eCAM REIT or the other investment options described in this handout will be achieved. Prospective investors must determine for themselves what reliance (if any) they should place on such statements, views, projections or forecasts and no responsibility is accepted by the Manager or any other representatives of the proposed eCAM REIT structure or wider eCAM Biomed Global Impact Fund structure in respect thereof. Prospective investors are strongly advised to conduct their own due diligence including, without limitation, the legal and tax consequences to them of investing in eCAM REIT or the other investment options described in this handout. It should be remembered that the price of limited partnership interests and the income from them can go down as well as up. Any website and information or links contained therein, whether or not related to eCAM REIT, are not part of this document and should not be considered as incorporated by reference herein. References to names of portfolio companies or investments may be made to the trading or brand name of the relevant group but relate, where the context requires, to the applicable holding company/ subsidiary of the relevant funds. Other than as set out above, no representation made or information given in connection with or relevant to an investment in eCAM REIT or the other investment options described in this handout may be relied upon as having been made or given with the authority of the Manager and/or general partner of eCAM REIT and no responsibility is accepted by such persons, their subsidiaries or associates or any of their directors, officers, employees or agents, in respect thereof. The delivery of this handout does not imply that the information herein is correct as at any time subsequent to the date hereof. It is the responsibility of prospective investors to satisfy themselves as to full compliance with the relevant laws and regulations of any territory in connection with any application to participate in eCAM REIT or the other investment options described in this handout, including obtaining any requisite governmental or other consent and adhering to any other formality prescribed in such territory. The attention of prospective investors is drawn to the fact that eCAM REIT is likely to be committing its funds to investments of a long term nature. There is no currently available public market for commitments in eCAM REIT and no such market is expected to develop until at the earliest the latter part of 2020 when it is intended to make application for the listing and trading of interests in eCAM REIT on appropriate recognised stock exchanges. Investors should note the considerations which will be set out under “Risk Factors” in the relevant Private Placement Memorandum. eCAM REIT and the other investment options described in this handout are not suitable for investment other than by sophisticated and/or high net worth investors who understand and are able to accept the risks involved in investing through eCAM REIT or the other investment options in the type of investments described herein, including the risk that all or a substantial portion of their investment cannot be returned either during the life of the investment structure or at all. All the trade-marks, service-marks and logos used or displayed in this document are registered, un-registered or otherwise protected intellectual property.
Essential Cancer Advanced Monitoring (eCAM™) advanced biomedical imaging with the eCAM Total-Body PET-CT system is for Doctors and Patients, and Pharma Tenants of eCAM Medical Plazas, in cooperation with leading global companies and institutions, for scalable global public and private healthcare benefit.

We’re always looking for great talent to join our committed global impact team. Contact us: